# Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate

> **NCT00385840** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 678 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza Vaccine GSK1247446A
- **BIOLOGICAL:** FluarixTM

## Key facts

- **NCT ID:** NCT00385840
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-20
- **Primary completion:** 2007-02-01
- **Final completion:** 2007-02-05
- **Target enrollment:** 678 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00385840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00385840, "Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00385840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*